Omiya, Japan

Toshiro Amamoto

This inventor holds 1 USPTO granted patent. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toshiro Amamoto. Retrieved from https://idiyas.com/inventor/toshiro-amamoto

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1990

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Toshiro Amamoto: Innovator in Antitumor Research

Introduction

Toshiro Amamoto is a notable inventor based in Omiya, Japan. He has made significant contributions to the field of biochemistry, particularly in the development of novel therapeutic compounds. His work focuses on creating innovative solutions for health-related challenges.

Latest Patents

Amamoto holds a patent for "Novel tripetide derivatives." This patent describes tripeptide derivatives of the formula ##STR1##, wherein R is a formyl group or a dimethoxymethyl group. These compounds have demonstrated antitumor and enzyme inhibition effects, showcasing their potential in medical applications.

Career Highlights

Toshiro Amamoto is associated with Taisho Pharmaceutical Co., Ltd., a leading company in the pharmaceutical industry. His role at the company has allowed him to explore and develop groundbreaking research in the field of medicinal chemistry.

Collaborations

Throughout his career, Amamoto has collaborated with esteemed colleagues, including Kazutoshi Mizoue and Tadayasu Okazaki. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Toshiro Amamoto's contributions to the field of biochemistry, particularly through his patent on novel tripeptide derivatives, highlight his role as an innovator in antitumor research. His work continues to influence the pharmaceutical industry and offers promising avenues for future medical advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…